Gide, counsel to the underwriters on the initial public offering of Innate Pharma on the Nasdaq for USD 79 million
14 November 2019
Deals | USA & France | International Capital Markets
Gide has advised Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group LLC and Citigroup Global Markets Limited (the "underwriters") on the initial public offering of Innate Pharma ("Innate") on the Nasdaq Global Select Market, through a capital increase reserved to a category of investors for an aggregate gross proceeds of USD 79 million, after full exercise of the over-allotment option.
Innate is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Gide advised the underwriters on the French law aspects of this transaction with a team composed of Arnaud Duhamel (partner) and Juliette Pierre (associate) in Paris and Théophile Strebelle (counsel) and Melanie Simon (associate) in New York. The underwriters were advised by Davis Polk & Wardwell LLP on the U.S. law aspects.
Innate was represented by Cooley LLP on the U.S. law aspects of this transaction and by Linklaters LLP on the French law aspects.